MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1-Reference-Cited by-同舟云学术

MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1

Published:2012-06-18 Issue:17 Volume:32 Page:2239-2246
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Gómez-Casares M T,García-Alegria E,López-Jorge C E,Ferrándiz N,Blanco R,Alvarez S,Vaqué J P,Bretones G,Caraballo J M,Sánchez-Bailón P,Delgado M D,Martín-Perez J,Cigudosa J C,León J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2012246.pdf

Reference47 articles.

1. Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F . The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253–264.

2. Eilers M, Eisenman RN . Myc’s broad reach. Genes Dev 2008; 22: 2755–2766.

3. Nesbit CE, Tersak JM, Prochownik EV . MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004–3016.

4. Vita M, Henriksson M . The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318–330.

5. Meyer N, Penn LZ . Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976–990.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia;Genes & Diseases;2023-10

2. CDK8/19 Inhibition Attenuates G1 Arrest Induced by BCR-ABL Antagonists and Accelerates Death of Chronic Myelogenous Leukemia Cells;2023-09-25

3. Tackling Imatinib Resistance via Au‐nanoconjugates using A Cml Resistant Cell Line;Particle & Particle Systems Characterization;2023-08-21

4. AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers;Molecular and Clinical Oncology;2023-02-08

5. The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation;Journal of Clinical Medicine;2022-01-10